Skip to main content

Table 4 Treatment characteristics by line of treatment

From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Treatment First-line Second-line Third-line Fourth-line
  n (%) n (%) n (%) n (%)
N 168 79 25 10
TKI 137 (81.5) 24 (30.4) 6 (24.0) 5 (50.0)
 Gefitinib 114 (83.2) 4 (16.7) 1 (16.7) 0 (0.0)
 Erlotinib 23 (16.8) 20 (83.3) 4 (66.7) 0 (0.0)
 Afatinib 0 (0.0) 0 (0.0) 1 (16.7) 5 (100)
CT 31 (18.5) 43 (54.4) 14 (56.0) 4 (40.0)
 Doublet 24 (77.4) 26 (60.5) 5 (35.7) 1 (25.0)
 Monochemotherapy 4 (12.9) 16 (37.2) 8 (57.1) 2 (50.0)
 Triplet 3 (9.7) 1 (2.3) 1 (7.1) 1 (25.0)
CT + maintenance TKI 8 (4.8) 1 (1.3) 0 (0.0) 0 (0.0)
CT + maintenance CT 2 (1.2) 1 (1.3) 0 (0.0) 0 (0.0)
Other 0 (0.0) 1 (1.3) 2 (8.0) 0 (0.0)
  1. CT Chemotherapy, TKI Tyrosine kinase inhibitor